MSS
Clinical trials for MSS explained in plain language.
Never miss a new study
Get alerted when new MSS trials appear
Sign up with your email to follow new studies for MSS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
Disease control Recruiting nowThis phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pM…
Matched conditions: MSS
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New combo therapy aims to boost survival in tough rectal cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study…
Matched conditions: MSS
Phase: PHASE3 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Triple threat: radiotherapy, chemo, and immunotherapy take on spread rectal cancer
Disease control Recruiting nowThis phase 2 trial is testing a new approach for people with a specific type of rectal cancer that has spread to a few other spots in the body (oligometastases). The treatment combines short-course radiotherapy, chemotherapy (CAPEOX), and an immunotherapy drug called serplulimab …
Matched conditions: MSS
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if …
Matched conditions: MSS
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC